

8th International Conference on Malignancies in AIDS and Other Immunodeficiencies

April 29-30, 2004

Main Auditorium, Natcher Conference Center
National Institutes of Health Campus, Bethesda, Maryland

Presented by the National Cancer Institute

Program

Thursday, April 29

8:00 AM – 6:00 PM **Poster Presentations**

8:30 AM **Opening Remarks and Welcome**

Jodi B. Black, Ph.D., Program Director, AIDS Malignancy Program, Division of Cancer Treatment and Diagnosis (DCTD), National Cancer Institute (NCI), National Institutes of Health (NIH)

8:40 - 9:55 AM **Plenary Lectures**

Moderator: Jodi B. Black, Ph.D., Program Director, AIDS Malignancy Program, DCTD, NCI, NIH

8:40 S1 Phase I Study of Interleukin-2 and Stem Cell Factor in Patients with AIDS or HIV and Cancer
Michael Caligiuri, M.D., Director, Ohio State University Comprehensive Cancer Center

9:05 S2 NIH HIV Vaccine Initiatives
Richard Koup, M.D., Senior Investigator and Chief, Immunology Laboratory, Vaccine Research Center, National Institute of Allergy and Infectious Diseases (NIAID), NIH

9:30 S3 Immune Response to Viruses
Louis Picker, M.D., Associate Director, Vaccine and Gene Therapy Institute, Director of the Vaccine Program, and Director, Pathobiology and Immunology Division, Oregon Health and Sciences University (OHSU)

9:55 AM Break

10:25 AM - 12:20 PM **Human Papillomavirus (HPV) Immunology**

Moderators: Joel Palefsky, F.R.C.P.(C), Director, Clinical Research Center, University of California, San Francisco (UCSF)
T-C Wu, M.D., Ph.D., Associate Professor of Pathology, Oncology, Obstetrics and Gynecology and Molecular Microbiology and Immunology, The Johns Hopkins University (JHU)

10:25 S4 HPV Infection in the Context of Highly Active Antiretroviral Therapy (HAART)
Joel Palefsky, M.D., F.R.C.P.(C), Director, Clinical Research Center, UCSF

10:45 S5 Development of HPV Human T Cell Mediated Assays
Chien-Fu Hung, Ph.D., Assistant Professor of Pathology, JHU

11:05 S6 Overview and Challenges to Assessing T Cell Responses to HPV
Malcolm John, M.D., M.P.H., Assistant Clinical Professor and Director, PositiveHealth Practice, UCSF

- 11:25 S7 Advances in the Immunology of HPV and the Continued Need for a Therapeutic HPV Vaccine
Martin Kast, Ph.D., Walter A. Richter Chair for Cancer Research, Norris Comprehensive Cancer Center, University of Southern California (USC)
- 11:40 S8 Investigational HPV (Types 6, 11, 16, 18) L1 VLP Vaccine - Development Update
Eliav Barr, M.D., Senior Director, Biologics Clinical Research, Merck Research Laboratories
- Noon S9 Update on the Development of an HPV-16/18 Prophylactic Cervical Cancer Vaccine
Gary Dubin, M.D., Vice President, Worldwide STD Vaccine Development, Programs and Adult Vaccine Franchise, GlaxoSmithKline Biologicals
- 12:20 PM Lunch
- 1:30 - **Abstract Presentations**
2:30 PM Moderator: Doug Lowy, M.D., Laboratory Chief, Laboratory of Cellular Oncology, Center for Cancer Research (CCR), NCI, NIH
- 1:30 1,2 Cancer Incidence and Survival Times Among Adults with AIDS in the Pre-HAART and HAART Eras
Nancy Hessol, M.S.P.H., Assistant Adjunct Professor, UCSF
- 1:45 3 Assessment of HPV DNA Testing as an Adjunct to Primary Cervical Cytologic Screening in HIV⁺ Women
Tiffany Harris, Ph.D., Instructor, Department of Epidemiology and Population Health, Albert Einstein College of Medicine
- 2:00 4 Artemisinin Is Cytotoxic for HPV-expressing Cervical Epithelial Cells but Not Primary Cervical Cells
Astrid Baega, M.D., Research Fellow, CCR, NCI, NIH
- 2:15 5 A Novel Therapy for Cervical Cancer Using Spliceosome-mediated RNA Trans-splicing
Michael Patrick, B.S., Graduate Student, CCR, NCI, NIH
- 2:30 PM Break
- 3:00- **Immunology and Oncogenesis**
4:00 PM Moderator: Cliona Rooney, Ph.D., Professor, Baylor College of Medicine
- 3:00 S10 Activation of CD21 and CD23 Gene Expression by Kaposi's Sarcoma Herpesvirus (KSHV) Replication and Transcription Activator (RTA)
Jae Jung, Ph.D., Professor of Microbiology and Molecular Genetics, Harvard Medical School
- 3:20 S11 Downregulation of MHC-I Molecules by Virally-encoded E3-ubiquitin Ligases
Laurent Coscoy, Ph.D., Assistant Professor of Immunology, University of California, Berkeley
- 3:40 S12 Improving Survival, Expansion and Persistence of Adoptively-transferred Tumor-specific CTLs
Cliona Rooney, Ph.D., Professor, Baylor College of Medicine
- 4:00 - **Abstract Presentations**
5:00 PM Moderator: Joseph Pagano, M.D., Professor of Medicine, University of North Carolina
- 4:00 6 The Mutator Pathway is a Feature of Immunodeficiency-related Lymphomas
Alex Duval, M.D., Ph.D., INSERM Institute
- 4:15 7 Expression of Activation Induced Cytidine Deaminase, Germinal Center B Cell Gene, Is Induced by Infection with Epstein-Barr Virus (EBV)
Marta Epeldegui, Ph.D. Candidate, University of California, Los Angeles

- 4:30 8 EBV Infection of NOD/SCID Mice Reconstituted with Human Hematopoietic CD34⁺ Cells
Miguel Islas-Ohlmayer, M.D., Post-doctoral Researcher, University of Texas Southwestern Medical Center
- 4:45 9 RRV-associated Malignancies in the SIV-infected Rhesus Macaque
Scott W. Wong, Ph.D., Associate Scientist, OHSU
- 5:00 PM Adjourn to posters

Friday, April 30

8:00 AM - **Poster Presentations**
6:00 PM

8:30 AM **Introductory Remarks**

Ellen G. Feigal, M.D., Vice President of Clinical Sciences and Deputy Scientific Director, Translational Genomics Research Institute (TGen)

8:40 - **Plenary Lectures**

9:35 AM Moderators: Ellen G. Feigal, M.D., Vice President of Clinical Sciences and Deputy Scientific Director, Translational Genomics Research Institute (TGen)
Michael Marco, International Program Coordinator, Adult AIDS Clinical Trials Group, Social and Scientific Systems

8:40 S13 Survey of Research in AIDS-Kaposi's Sarcoma (KS) in Zimbabwe
Margaret Borok, M.D., Senior Lecturer, University of Zimbabwe College of Health Sciences

9:10 S14 Cervical Cancer Prevention - A Paradigm Shift?
Lynette Denny, M.B., Ch.B., M.M.E.D., Ph.D., F.C.O.G. (SA), Associate Professor and Senior Specialist, University of Cape Town, South Africa

9:35 - **Clinical Session: Bone Marrow Transplantation for AIDS-related Lymphoma**

10:35 AM Moderators: David T. Scadden, M.D., Director, Hematologic Malignancies and Experimental Hematology and Co-Director, AIDS Research Center, Massachusetts General Hospital and Harvard Medical School
Lawrence Kaplan, Clinical Professor of Medicine, UCSF and Program Member, UCSF Comprehensive Cancer Center

9:35 S15 Autologous Stem Cell Transplantation for AIDS-related Lymphoma: AIDS Malignancy Consortium 020
David T. Scadden, M.D., Director, Hematologic Malignancies and Experimental Hematology and Co-Director, AIDS Research Center, Massachusetts General Hospital and Harvard Medical School

9:45 S16 Long Term Remission with Autologous Stem Cell Transplantation in High Risk HIV Associated Lymphoma
Amrita Y. Krishnan, M.D., Staff Physician, City of Hope Comprehensive Cancer Center

10:00 S17 High-dose Therapy Plus Autologous Hematopoietic Stem Cell Transplantation for HIV-related Lymphoma: Results and Impact on HIV Disease
Jean Gabarre, M.D., Hôpital Pitié-Salpêtrière, France

10:15 10,11 Clinical Outcome and Immunoreconstitution in HIV-related Lymphomas After High Dose Therapy and Peripheral Blood Stem Transplantation
Cecilia Simonelli, M.D., Division of Medical Oncology A, National Cancer Institute, Aviano, Italy

10:25 Discussion

- 10:35 AM Break
- 11:00 AM - **Abstract Presentations**
 Noon Moderators: Elliott Kieff, M.D, Ph.D., Harriett Ryan Albee Professor of Microbiology and Molecular Genetics, Co-Director, Channing Laboratory, Harvard Medical School, and Senior Physician, Brigham and Women's Hospital
 Alexandra M. Levine, M.D., Distinguished Professor of Medicine, Chief of Hematology, and Ronald H. Bloom Family Chair in Lymphoma, USC School of Medicine and Medical Director, Norris Cancer Hospital and Research Institute
- 11:00 12 Treatment of SCID Mice with a Statin Inhibits the Development of EBV-associated Lymphoma
 Jeffrey Cohen, M.D., Jeffrey Cohen, M.D., Head of Medical Virology Section, Laboratory of Clinical Infectious Diseases, NIAID, NIH
- 11:15 13 Antiviral Targeting of NF- κ B and EBV Viral Latency in Burkitt Lymphoma
 William Harrington, Jr., M.D., Assistant Professor of Hematology/Oncology, University of Miami School of Medicine
- 11:30 14 Liposome Encapsulated Doxorubicin (TLC D-99, MyocetTM) with Cytosan, Vincristine and Prednisone for AIDS-related Lymphoma: Therapy Results and Correlates of Response
 Anil Tulpule, M.D., Assistant Professor of Medicine, USC and Norris Cancer Hospital and Research Institute
- 11:45 15 Phase I Trial of Antisense Oligo Against Vascular Endothelial Growth Factor (VEGF-AS, Veglin) in Relapsed and Refractory Malignancies
 Alexandra M. Levine, M.D., Distinguished Professor of Medicine, Chief of Hematology, and Ronald H. Bloom Family Chair in Lymphoma, USC School of Medicine and Medical Director, Norris Cancer Hospital and Research Institute
- Noon Lunch
- 1:00 - **Viral Load Assays: Utility and Issues**
 1:45 PM Moderator: Richard F. Ambinder, M.D., Ph.D., Director, Division of Hematologic Malignancies, JHU School of Medicine
- 1:00 S18 Altered EBV Viral Setpoint Due to HIV-Related Immune Activation
 Debbie van Baarle, Ph.D., Sanquin Blood Supply Foundation, The Netherlands
- 1:15 S19 Real Time Quantitative PCR Assays for Accurately Measuring Viral Load of HTLV, KSHV, EBV, HIV, HCV AND HBV: Uses and Potential Pitfalls
 Denise Whitby, Ph.D., Head of Viral Epidemiology Section, AIDS Vaccine Program, NCI, NIH
- 1:30 S20 EBV AND KSHV Copy Number in Hodgkin's Lymphoma and AIDS Lymphoma
 Richard F. Ambinder, M.D., Ph.D., Director, Division of Hematologic Malignancies, JHU School of Medicine
- 1:45 - **Abstract Presentations**
 2:30 PM Moderator: Robert Yarchoan, M.D., Branch Chief, HIV & AIDS Malignancy Branch, CCR, NCI, NIH
- 1:45 16 Flare of AIDS-associated KS Following HAART: A Manifestation of Immune Reconstitution Syndrome
 David Aboulafia, M.D., Clinical Professor, University of Washington School of Medicine
- 2:00 17 Associations of Classic KS with Haplotypes of IL8, IL8RB, and IL13
 Elizabeth E. Brown, M.P.H., Ph.D., Cancer Research Postdoctoral Fellow, NCI, NIH

- 2:15 18 KSHV Induced Angiogenesis and Differentiation to Lymphatic Endothelium
Michael Lagunoff, Ph.D., Assistant Professor of Microbiology, University of Washington
- 2:30 PM Break
- 3:00 - **Pathogenesis and Viral Oncology Session**
4:00 PM Moderator: Patrick Moore, M.D., M.P.H., Director, Molecular Virology Program, University of Pittsburgh Cancer Institute and Hillman Cancer Center
- 3:00 S21 Rethinking the Pathogenesis of KS
Donald E. Ganem, M.D., Professor of Microbiology and Immunology, UCSF
- 3:20 S22 The Latency-associated Nuclear Antigen of KSHV Modulates Cellular Gene Expression and Protects Lymphoid Cells From p16ink4a-induced Cell Cycle Arrest
Rolf Renne, Ph.D., Assistant Professor of Molecular Biology and Microbiology, Case Western Reserve University
- 3:40 S23 Tumorigenic Mechanisms of KSHV
Ashlee Moses, Ph.D., Assistant Scientist, Vaccine and Gene Therapy Institute, OHSU
- 4:00 - **Abstract Presentations**
5:00 PM Moderator: Denise Whitby, Head of Viral Epidemiology Section, AIDS Vaccine Program, NCI, NIH
- 4:00 19 KSHV and RRV Capsid Structure at ≤ 10 Å Resolution and Identification of RRV- associated Proteins by Tandem Mass Spectrometry
Christine M. O'Connor, B.S., Graduate Student, University of Virginia
- 4:15 20 LANA Mediated Intranuclear Shuttling of KSHV Genomes
Magdalena Weidner, B.S., Graduate Student, Kimmel Comprehensive Cancer Center, JHU
- 4:30 21 KSHV/HHV-8 Replication and Transcription Activator Regulated Both Viral and Cellular Genes by Binding to Interferon-Stimulated Response Element
Luwen Zhang, Ph.D., Assistant Professor of Virology, University of Nebraska
- 4:45 22 A Second Self-reinforcing Loop Involving JUN/FOS, RTA, and RAP Drives KSHV Lytic Cycle Reactivation in PEL Cells at Earlier Stages than the C/EBPA, RTA, and RAP Loop
Gary Hayward, M.D., Professor of Oncology, Pathology, Pharmacology, and Molecular Sciences, JHU School of Medicine
- 5:00 PM Adjourn to posters

Continuing Medical Education

The National Institutes of Health/Foundation for Advanced Education in the Sciences (NIH/FAES) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The NIH/FAES designates this education activity for a maximum of 13 hours in category 1 credit toward the AMA Physician's Recognition Award. Each physician should claim only those hours of credit that he/she actually spent in the activity. The CME form is available at the registration desk outside the main auditorium.

DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
National Cancer Institute